Related Experiment Video
Updated: Mar 22, 2026
06:44
Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
Published on: April 13, 2018
10.6K
MMP-3-1612 polymorphism - a risk factor for deep venous thrombosis formation
La-Mei Yu1, Nai-Xuan Li2, Yu-Guo Sheng2
1Department of Physiology, Binzhou Medical University, Yantai, P. R. China.
VASA. Zeitschrift Fur Gefasskrankheiten
|April 30, 2016
Summary
The 5A allele of the matrix metalloproteinase-3 gene (MMP-3-1612) promoter polymorphism is linked to higher serum MMP-3 levels. This elevated MMP-3 may increase the risk of deep venous thrombosis (DVT).
Area of Science:
- Genetics
- Molecular Biology
- Thrombosis Research
Background:
- Investigated the association between the matrix metalloproteinase-3 gene (MMP-3) promoter polymorphism (-1612 5A/6A) and deep venous thrombosis (DVT).
- MMP-3 plays a role in extracellular matrix remodeling, potentially influencing vascular health.
Purpose of the Study:
- To determine if the MMP-3-1612 5A/6A polymorphism is associated with DVT.
- To explore the relationship between MMP-3 gene expression and DVT development.
Main Methods:
- Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to genotype the MMP-3-1612 polymorphism.
- Enzyme-linked immunosorbent assay (ELISA) to measure serum MMP-3 levels in patients and controls.
- In vitro luciferase assays to assess the transcriptional activity of MMP-3 alleles.
- A DVT rat model to study MMP-3 levels during thrombosis formation.
Main Results:
- Significantly higher frequency of the MMP-3-1612 5A allele and elevated serum MMP-3 levels were observed in the DVT case group compared to the control group (P < 0.05).
- The 5A allele demonstrated higher transcriptional activity than the 6A allele in vitro.
- Serum MMP-3 levels increased over time in the DVT rat model, correlating with thrombosis progression.
Conclusions:
- The MMP-3-1612 5A/6A polymorphism influences serum MMP-3 levels.
- Overexpression of serum MMP-3 may represent a risk factor for the development of deep venous thrombosis.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
655
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
655
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
429
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
429
01:29Venous Thrombosis III: Interprofessional Care
459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
106
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:30Venous Thrombosis IV: Nursing Management
364
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
364